apixaban
bms,pfizer
['apollo', 'apixaban']
apollo trial just presented at #esc2022 by showing no benefit of profilatic apixaban 2.5 mg twice day in outpatients with covid-19 and risk factors for vte. 
Mom of 3,cardiologist,MHS. BCRI Faculty. VP Cardio-Onc Chapter Braz Society Cardiology #Cardioprotection #Amyloidosis#Thrombosis #HF #WIHC